Advances in vaccine adjuvants

Area of Science:

• Immunology and Vaccinology
• Biotechnology and Pharmaceutical Sciences

Background:

• Current approved vaccine adjuvants (aluminum salts, MF59) are limited.
• Newer, less immunogenic vaccines necessitate the development of more potent adjuvants.
• Intensified research focuses on novel immunostimulatory molecules and particulate adjuvants.

Purpose of the Study:

• To review promising novel vaccine adjuvants beyond currently approved options.
• To evaluate the potential of immunostimulatory molecules, particulate adjuvants, and CpG oligonucleotides.
• To highlight the need for further research into adjuvant mechanisms and therapeutic applications.

Main Methods:

• Review of preclinical and early human trial data for novel adjuvant candidates.
• Evaluation of immunostimulatory molecules (MPL, QS21), particulate adjuvants (MF59, Iscoms), and CpG oligonucleotides.
• Assessment of immune response elicitation (humoral and cellular) and safety profiles.

Main Results:

• Immunostimulatory molecules (MPL, QS21) show promise but raise safety concerns.
• Particulate adjuvants (MF59, Iscoms) are potent inducers of humoral and cellular immunity.
• CpG oligonucleotides demonstrate encouraging potential for selective immune response modulation.

Conclusions:

• Novel adjuvants offer enhanced immunogenicity for next-generation vaccines.
• Further investigation into adjuvant mechanisms is crucial for optimizing their use.
• Development of potent adjuvants could enable therapeutic vaccine applications.